Use of trimethazine in preparation of drugs for preventing and treating liver diseases

Abstract

Disclosed is a use of trimethazine in the preparation of drugs for preventing and treating liver diseases. Trimethazine is capable of inhibiting activation of resting T-cells to activated lymphocytes, reducing release of cytokines, and reducing hepatocyte injury caused by immune system; inhibiting fatty acid metabolism in hepatocytes, and optimizing the energy process in hepatocytes; and maintaining normal function of mitochondrial permeability transition pores, and reducing hepatocyte apoptosis. Trimethazine has the efficacy of maintaining the liver functions, and reducing transminase (comprising glutamic pyruvic transaminase, glutamic oxalacetic transaminase, etc.).

1 - 4 . (canceled) 
     
     
         5 . A method for treating acute-on-chronic liver failure, comprising administrating to a subject in need thereof a pharmaceutical composition comprising an effective amount of trimetazidine or a pharmaceutically acceptable salt thereof as an active ingredient. 
     
     
         6 . The method according to  claim 5 , wherein the pharmaceutical composition is orally administered to the subject. 
     
     
         7 . The method according to  claim 5 , wherein the pharmaceutical composition is parentally administered to the subject. 
     
     
         8 . The method according to  claim 5 , wherein the pharmaceutical composition is administered to the subject 1-4 times daily. 
     
     
         9 . The method according to  claim 5 , wherein the pharmaceutical composition is administered to the subject 2 or 3 times daily. 
     
     
         10 . The method according to  claim 5 , wherein the subject is administered with about 30-180 mg daily of trimetazidine or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The method according to  claim 5 , wherein the subject is administered with about 60 mg daily of trimetazidine or a pharmaceutically acceptable salt thereof. 
     
     
         12 . The method according to  claim 5 , wherein active ingredient of the pharmaceutically composition consists essentially of trimetazidine or a pharmaceutically acceptable salt thereof. 
     
     
         13 . The method according to  claim 5 , wherein active ingredient of the pharmaceutically composition consists of trimetazidine or a pharmaceutically acceptable salt thereof. 
     
     
         14 . The method according to  claim 5 , wherein the pharmaceutically composition further comprises a pharmaceutically acceptable carrier. 
     
     
         15 . The method according to  claim 5 , wherein the pharmaceutically composition reduces activation of resting T lymphocytes to activated lymphocytes in the subject. 
     
     
         16 . The method according to  claim 5 , wherein the pharmaceutically composition reduces fatty acid metabolism in hepatocytes and promotes aerobic oxidation of glucose in the subject. 
     
     
         17 . The method according to  claim 5 , wherein the pharmaceutically composition reduces β-oxidation in hepatocytes and reduces formation of ROS in the subject. 
     
     
         18 . The method according to  claim 5 , wherein the pharmaceutically composition reduces blood alanine aminotransferase (ALT) level in the subject. 
     
     
         19 . The method according to  claim 5 , wherein the pharmaceutically composition reduces blood aspartate transaminase (AST) level in the subject. 
     
     
         20 . The method according to  claim 5 , wherein the subject is not suffering from angina pectoris, coronary insufficiency, previous myocardial infarction, coronary heart disease, vertigo or tinnitus.